Veracyte Inc
NASDAQ:VCYT

  • LAST PRICE
    35.9400
  • TODAY'S CHANGE (%)
    -1.1000 (-2.9698%)
  • Bid / Lots
    34.0000/ 1
  • Ask / Lots
    35.9000/ 1
  • Open / Previous Close
    37.7600 / 37.0400
  • Day Range
    35.3700
    37.7600
  • 52 Week Range
    18.6100
    41.4300
  • Volume
    1,626,863

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
VCYT
Veracyte Inc
2.8B
-248.8x
---
FOLD
Amicus Therapeutics Inc
3.0B
-28.0x
---
CPRX
Catalyst Pharmaceuticals Inc
2.6B
17.6x
---
ZLAB
Zai Lab Ltd
2.8B
-9.7x
---
BEAM
Beam Therapeutics Inc
2.2B
-14.0x
---
APLS
Apellis Pharmaceuticals Inc
3.5B
-12.9x
---
As of 2024-11-15

Company Information

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Contact Information

Headquarters
6000 Shoreline Court, Suite 300SOUTH SAN FRANCISCO, CA, United States 94080
Phone
650-243-6300
Fax
650-243-6301

Executives

Independent Chairman of the Board
Robert Epstein
Chief Executive Officer, Director
Marc Stapley
Chief Financial Officer
Rebecca Chambers
Chief Human Resource Officer, General Counsel
Annie Mcguire
Chief Scientific Officer, Chief Medical Officer
Phillip Febbo

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$2.8B
Revenue (TTM)
$425.3M
Shares Outstanding
76.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.65
EPS
$-0.14
Book Value
$14.25
P/E Ratio
-248.8x
Price/Sales (TTM)
6.7
Price/Cash Flow (TTM)
199.3x
Operating Margin
-5.53%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.